research ANDROGENETIC ALOPECIA
Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Bone density is normal in male rats treated with finasteride.
Finasteride doesn't affect bone density in male rats.
research In Vivo Time-Dependent Inhibition of Human Steroid 5a-Reductase by Finasteride
Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
research Clinical applications of antiandrogens
Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.
research Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5α-reductase inhibitor
Finasteride temporarily lowers male rat fertility without affecting libido.
research Resveratrol derivatives: a patent review (2009 – 2012)
New resveratrol-related compounds show promise for treating various health issues but need more research for clinical use.
research Androgen antagonists in androgen target tissues
Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
research Minoxidil
Minoxidil effectively treats hair loss, works better for women, and requires consistent use.
research Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the Male
Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
research Alopecia: unapproved treatments or indications
Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.
research The Role of Non-Aromatizable Testosterone Metabolite in Metabolic Pathways
Normal levels of DHT can reduce belly fat and increase muscle, but too much can lead to hair loss, prostate issues, and possibly heart disease.
research 5α‐Reductase inhibitors and prostatic disease
5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway
DA-9401 helps protect rat testis from finasteride damage.
research 5α-Reductase Inhibitors, Chemical and Clinical Models
Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research The Effect of Anti-Androgens on the Response of Rat Preputial Glands to Testosterone*
New compounds can block testosterone effects in rats and might help treat conditions like prostate cancer and acne.
research Saturable Binding of Finasteride to Steroid 5α-reductase as Determinant of Nonlinear Pharmacokinetics
Finasteride's effect on hair loss and prostate enlargement depends on its binding to an enzyme, with maximum impact at 0.2 mg dose.
research Synthesis and Pharmacological Evaluation of New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors
Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
research 3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1
A new compound effectively inhibits human 5α-reductase 1.
![Effect of C-Ring Modifications in Benzo[c]quinolizin-3-ones, New Selective Inhibitors of Human 5α-Reductase 1](/images/research/c687900f-ea40-4de1-8f0b-a5b818951b1c/small/15452.jpg)
research Effect of C-ring modifications in benzo[c]quinolizin-3-ones, new selective inhibitors of human 5α-reductase 1
Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
research Lack of effect of topical finasteride suggests an endocrine role for dihydrotestosterone
Topical finasteride doesn't reduce DHT levels, hinting at an endocrine role in hair loss.
research Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors
Natural herbal compounds might treat certain medical conditions by reducing DHT levels, but more research is needed to confirm their effectiveness and safety.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research 5α-Metabolism in Finasteride-Treated Subjects and Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency
Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.
research Bone density is normal in male rats treated with finasteride
Finasteride doesn't affect bone density in male rats.
research Post-finasteride syndrome – does it really exist?
Post-finasteride syndrome's existence is uncertain; more research needed.
research Androgenic alopecia may have evolved to protect men from prostate cancer by increasing skin exposure to ultraviolet radiation
Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.